3D ear made of living cells transplanted successfully
-
Loading... - Aadya Rana
- 14 Jun 2022
- 262 Views
- 0 Like
- 0 Comment
A medical team said Thursday they had reconstructed a human ear using the patient's own tissue to create a 3D bio-implant, a pioneering procedure they hope can be used to treat people with a rare birth defect.
The surgery was performed as part of an early-stage clinical trial to evaluate the safety and efficacy of the implant for people with microtia, in which the external ear is small and not formed properly.
AuriNovo, as the implant is called, was developed by the company 3DBio Therapeutics while the surgery was led by Arturo Bonilla, founder and director of the Microtia-Congenital Ear Deformity Institute.
"As a physician who has treated thousands of children with microtia from across the country and around the world, I am inspired by what this technology may mean for microtia patients and their families," Bonilla said in a statement.
He said he hoped the implant would one day replace the current treatment for microtia, which involves either grafting cartilage from a patient's ribs or using synthetic materials, porous polyethylene (PPE), to reconstruct outer ears.
The procedure involves 3D scanning the patient's opposite ear to create a blueprint, then collecting a sample of their ear cartilage cells and growing them to a sufficient quantity.
These cells are mixed with collagen-based bio-ink, which is shaped into an outer ear. The implant is surrounded by a printed, biodegradable shell, to provide early support, but which is absorbed into the patient's body over time.
The implanted ear is supposed to mature over time, developing the natural look and feel, including elasticity, of a regular ear.
The clinical trial expects to enroll 11 patients and is being conducted.
Bonilla said: "The AuriNovo implant requires a less invasive surgical procedure than the use of rib cartilage for reconstruction. We also expect it to result in a more flexible ear than reconstruction with a PPE implant." Read More...
